Surveillance for Merkel Cell Carcinoma Recurrence

Dr. Lisa Zaba, an Associate Professor of Dermatology at Stanford, discussed recent advancements in surveillance techniques for Merkel Cell Carcinoma (MCC) recurrence during her presentation. With a high recurrence rate of approximately 40%, early detection is crucial for effective treatment. Zaba highlighted the significance of utilizing circulating tumor DNA (ctDNA) for monitoring patients, a method that has shown a sensitivity of about 95% and specificity ranging from 86-90%. Compared to traditional imaging methods like PET scans, ctDNA can detect recurrences sooner, although interpretations may vary based on the ctDNA levels. The talk emphasized the importance of timely referrals to specialized centers for initial staging and treatment, followed by vigilant surveillance protocols that incorporate blood tests for ctDNA and, for select patients, the A-merck test (which detects antibodies against the Merkel cell virus). Through patient case studies, Zaba illustrated diverse outcomes based on the implementation of these tests, underscoring the potential for early intervention and the need for specialized support. The comprehensive approach to MCC care combines technological advancements with clinical expertise, demonstrating a significant evolution in how practitioners can manage and surveil this aggressive cancer.